• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ESMO: Bristol Myers axes Immatics' bispecific after $150M bet

cafead

Administrator
Staff member
  • cafead   Sep 16, 2024 at 10:12: AM
via Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific molecule that BMS picked up for $150 million upfront late in 2021.

article source
 

<